425: AlloVir and Kalaris Therapeutics Announce Merger to Advance Novel Retinal Disease Therapy

AlloVir and Kalaris Therapeutics have entered into a definitive merger agreement to focus on developing Kalaris' lead asset, TH103, a novel anti-VEGF therapy for retinal diseases.

Summary

• AlloVir and Kalaris Therapeutics have announced a definitive merger agreement.
• Post-merger, pre-merger AlloVir stockholders are expected to own approximately 25.05% of the combined company, while pre-merger Kalaris stockholders are expected to own approximately 74.95%.
• The combined company is expected to have approximately $100 million in cash at closing, sufficient to fund operations until the end of 2026.
• The merger is expected to close in the first quarter of 2025, with the company renaming to Kalaris Therapeutics and trading under the ticker symbol KLRS on the NASDAQ.
• The focus will be on advancing TH103, a novel anti-VEGF therapeutic candidate for retinal diseases, designed by Dr. Napoleone Ferrara.
• TH103 has shown increased anti-VEGF activity and sustained retention in the retina in preclinical studies compared to aflibercept.
• A Phase 1 clinical trial for TH103 in treatment-naive wet AMD patients is currently enrolling, with initial data expected in the third quarter of 2025.
• The global market for branded anti-VEGF agents is approximately $14 billion and is projected to grow to $18 billion by 2029.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to the merger's potential to create value, the promising preclinical data for TH103, and the experienced management team. The focus on a large and growing market also contributes to the positive sentiment.

Positives

• The merger creates a company with a strong cash position to advance TH103 through clinical development.
• TH103 has the potential to be a transformative therapy in a large and growing market.
• The combined company has an experienced management team and board with expertise in ophthalmology and retinal diseases.
• Preclinical data suggests TH103 may offer advantages over existing anti-VEGF therapies.
• The Phase 1 trial includes a design to potentially allow for within-subject data comparisons with aflibercept.

Negatives

• Pre-merger AlloVir stockholders will own a minority stake (approximately 25.05%) in the combined company.
• The success of the merger is dependent on the successful development and commercialization of TH103, which is still in early clinical stages.
• The company will need to raise additional capital beyond 2026 to continue development if TH103 is not successful.

Risks

• The merger is subject to customary closing conditions, including stockholder approval.
• Clinical trials may be delayed or unsuccessful.
• The combined company may not be able to obtain regulatory approval for TH103.
• Competition in the anti-VEGF market is intense.
• The company may not be able to protect its intellectual property rights.

Future Outlook

The combined company will focus on advancing TH103 through clinical development, with initial Phase 1 data expected in Q3 2025 and further data in H1 2026. They plan to initiate a Phase 2 repeat dose clinical trial of TH103.

Management Comments

• David Hallal: 'Collectively we believe this merger represents the best interests of the stockholders of both AlloVir and Kalaris with the opportunity to create significant value for patients and shareholders.'
• Andrew Oxtoby: 'With TH103, we truly believe we have the opportunity to potentially bring something remarkable to the treatment of retinal disease.'

Industry Context

The merger reflects a growing interest in novel therapies for retinal diseases, particularly those that can improve upon existing anti-VEGF treatments by offering longer duration of action and improved patient outcomes. The anti-VEGF market is dominated by a few key players, and TH103 aims to address unmet needs related to treatment burden and suboptimal real-world outcomes.

Comparison to Industry Standards

• TH103 is being compared to aflibercept (Eylea), a market-leading anti-VEGF agent, in preclinical studies.
• The goal is to demonstrate superior anti-VEGF activity and longer duration of action compared to existing therapies like aflibercept and ranibizumab (Lucentis).
• The clinical trial design includes a component to compare TH103 to aflibercept within the same patients, which is a rigorous approach to assessing potential benefits.
• The $14 billion anti-VEGF market is dominated by companies such as Regeneron (Eylea) and Novartis (Lucentis).

Management Changes

Stakeholder Impact

• Shareholders of both AlloVir and Kalaris are expected to benefit from the merger through potential value creation.
• Patients with retinal diseases may benefit from the development of TH103, a potentially improved anti-VEGF therapy.
• Employees of both companies may experience changes as a result of the merger.

Next Steps

• Obtain stockholder approval for the merger.
• Close the merger in the first quarter of 2025.
• Rename the company to Kalaris Therapeutics and begin trading under the ticker symbol KLRS.
• Continue enrolling patients in the Phase 1 clinical trial of TH103.
• Share initial data from Part 1 of the Phase 1 study in the third quarter of 2025.
• Initiate a Phase 2 repeat dose clinical trial of TH103.

Key Dates